1. Cochrane methodology registry. In: The Cochrane Library. Oxford 2001.
2. Sacket D.L., Straus S.E. Finding and applying evidence during clinical rounds. JAMA 1998; 280: 1336-1338.
3. Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология (основы доказательной медицины). М: Медиа Сфера 1998; 352.
4. De Gruttola V.G., Clax P., DeMets D.L. et al. Consideration in the evaluation of surrogate endpоints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22 (5): 485-502.
5. Woodruff P.G., Modrek B., Choy D.F. et al. T-helper type 2-driven inflammation defines major sub phenotypes of asthma. Am J Respir Crit Care Med 2009; 180 (5): 388-395.
6. Micheel C.M., Ball J.R., eds. Committee on Qualification of Biomarkes and Surrogate Endpoints in Chronic Disease; Institute of Medicine. Evaluation of Biomarkes and Surrogate Endpoints in Chronic Disease. 2010.
7. Waterer G. Modern Diagnosis of Community Acquired and Viral Pneumonia: Beyond Conventional Microbiology Culture. Proceedings American Thoracic Society, Postgraduate course #3,4/12.
8. Porcel J.M., Ruiz-González A., Falguera M. et al. Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia. Chest 2007; 131 (5): 1442-1447.
9. Murdoch D.R., Laing R.T., Cook J.M. The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD. Clin Infect Dis 2003; 37 (1): 153-154.
10. Rello J., Ausina V., Ricart M. et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. 1993. Chest 2009; 104 (4): 1230-1235.
11. Perlino C. Alcoholism, leukopenia, and pneumococcal sepsis. Am Rev Respir Dis 1984; 132: 757-760.
12. Carlos W.G., Hage Ch.A. Advances in the non-culture based laboratory diagnosis of cryptococcus and endemic molds. Curr Fungal Infect Rep 2012; 6 (3): 215-220.
13. Cattamanchi A. Moving beyond smear and culture: rapid diagnosis of tuberculosis and identification of drug resistance. Proceedings American Thoracic Society, 2013. Posgratuate course #3, 1-18.
14. Light R.W., Lee G., Lee Y.C.G. Textbook of Pleural Disease. Hodder Arnold 2008; 650.
15. Light R.W., Lee Y.C. Pneumothorax, Chylothorax, Hemothorax, Fibrothorax. In Murray and Nadel's Textbook of respiratory disease. 5th ed. 2010; 2400.
16. Боткин С.П. Клинические лекции. Под ред. А.Л. Мясникова. 1952.
17. Sethi S., Wrona C., Eschberger K. et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. AJRCCM 2008; 177 (5): 491-495.
18. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Critical care 2010; 14 (1): 15.
19. Calfee C. Novel biomarkers in ARDS. Proceedings American Thoracic Society 2013. Postgratuate course #3.
20. Agrawal S. et al. COPD Pulmonary disease, chronic obstructive, severe early-onset. AJRCCM 2013 (in press).

________________________________________________

A.G. CHUCHALIN

Pulmonology Research Institute, Federal Biomedical Agency of Russia, Moscow